Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.
The company, a division of BGI Group, sold 40.1 million shares at RMB 13.64 per share for a total of RMB 547 million ($80.6 million) in the offering.
The firm began offering its common shares on Wednesday at $6 per share on the Nasdaq. Gross proceeds from the IPO were $7.1 million.
The molecular diagnostics firm said in an amended prospectus that it plans to offer 1.3 million shares of its common stock at between $6.35 and $6.75 per share.
Samsung Biologics debuted last week in Seoul with the largest IPO in South Korea in years, according to the Associated Press.
The IPO amount is about half of what the company's competitors, Editas Medicine and Intellia Therapeutics, raised in their own IPOs earlier this year.
In a filing with the US Securities and Exchange Commission, the company said it intends to sell up to $90 million in common stock on the Nasdaq.
The molecular diagnostic company plans to avoid the IPO process but go public in China through a reverse merger with an auto parts maker.
A billionaire entrepreneur is taking his highly valued firm NantHealth public.
The company did not specify the number of shares it will offer or the offering price, but said it intends to trade on the Nasdaq Global Market.
The New York Times reports that as China invests in science, it also is dealing with research fraud.
In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.
The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.
Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.